Multidisciplinary treatment planning (MTP) is a process of engaging multiple disciplines to develop or refine the disease management plan. It is widely implemented in US cancer treatment settings and is considered to have favorable effects on both care quality and other outcomes. However, evidence reviews to date regarding MTP effectiveness have based their conclusions on studies conducted predominantly outside the United States. The authors conducted a systematic review of US-based studies to synthesize and critically appraise evidence of the effects of MTP on cancer care quality, health services outcomes, and survival. Database searches identified studies of MTP outcomes conducted in US cancer care settings from 2000 to 2017. Forty-five studies met criteria for inclusion. MTP was associated with favorable effects on several indicators of cancer care quality, including delivery of guideline-concordant treatment and improvements in diagnostic accuracy, staging completeness, surgical technique, and timeliness. Effects on survival and clinical trials enrollment were mixed. Delivery formats for MTP were generally not well described, and study designs were nonrandomized, limiting the ability to identify mediators of intervention effects. Continued study is warranted to clarify effective components of MTP interventions, and to understand the mechanism(s) through which MTP produces favorable effects on outcomes. Cancer 2018;124:3656-3667. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
INTRODUCTION
Multidisciplinary treatment planning (MTP) is a collaborative process engaging multiple disciplines to develop or refine the disease management plan at critical junctures along the cancer care trajectory and is an essential component of quality cancer care. 1, 2 Although it is defined as an essential component of quality cancer care, 3 evidence of its effects on outcomes within US cancer care settings has not been synthesized. Because US cancer care settings may have distinctive organizational and operational features compared with settings in industrialized nations with single-payer and/or universal coverage, understanding the characteristics of MTP and its effects specifically within US-based settings is warranted. Therefore, we conducted a systematic review to characterize the formats used to deliver MTP and critically appraise the evidence of the effects of MTP on quality, patient-focused, and health services outcomes in US cancer care settings.
More than a dozen systematic reviews have appraised the evidence regarding MTP. However, the strength of the conclusions that can be drawn from these reports with respect to the effects of MTP on outcomes in US cancer care settings is restricted by the inclusion of studies conducted outside the United States, 4 a broad emphasis on multidisciplinary care rather than treatment planning, 5 focus on a specific cancer site 6, 7 or a narrower outcome, such as cost 8 or comorbidity. 9 Our systematic review extends the conclusions of prior reviews by: 1) focusing on MTP effectiveness and outcomes solely in US cancer care settings, 2) simultaneously examining a comprehensive set of outcomes (eg, guideline concordance, timeliness, and cost) across multiple disease sites and delivery formats, and 3) incorporating recently published studies. We defined MTP as the convening of oncology specialty providers and other disciplines (such as nursing, social work, and navigators) for the purposes of developing and modifying a consensus-based treatment plan, including supportive and rehabilitative care needs and planning for transitions in care (see Figure 1 ).
Cancer September 15, 2018 METHODS Electronic database searches identified studies of MTP outcomes conducted in cancer care settings and published from January 2000 through September 2017. The electronic search strategy is detailed in the online supporting information. Reference lists were also hand searched. The studies included evaluated the outcomes or effects of MTP; were conducted within US-based, adult cancer care settings; and were published in English. Studies were excluded if they included cancer as part of a mixed sample with other chronic diseases, did not report MTP outcomes, or described clinical standards for multidisciplinary management. We also excluded studies that solely addressed molecular tumor boards. Figure 2 details the study selection process. 10 Included studies (N = 45) were appraised by 2 authors using quality criteria of the National Heart, Lung, and Blood Institute that grade methodologic rigor according to study design. 11 The authors assigned a summary grade of "good" (little risk of bias), "fair" (some risk of bias but does not invalidate results), or "poor" (high risk of bias). Inter-rater disagreements were adjudicated by 1 author (S.A.M.).
RESULTS
The methodological quality of the included studies was judged as good (n = 19), fair (n = 24), or poor (n = 2). In 40 of 45 studies, MTP was examined in the setting of a single disease site, most commonly liver (n = 7), lung/ thoracic (n = 6), head/neck (n = 6), or gastrointestinal cancers (n = 6). Study designs were generally those with a high risk of bias (uncontrolled [n = 19] or historic controls [n = 16]), and approximately one-third of the studies reported outcomes qualitatively (n = 17) rather than applying statistical tests of differences (n = 28). There was also notable variation in how several of the outcome indicators were measured. For example, although timeliness typically was measured as the time from diagnosis to treatment initiation, some studies operationalized timeliness as the time from definitive surgery to initiation of systemic treatment or radiotherapy or the time from appointment to clinic visit.
Structural and Operational Components of MTP
Three formats for MTP were observed. Conference formats (n = 20) [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] convened various disciplines to review cases and reach a consensus about overall management. Activities included reviewing pathology, molecular, or imaging studies; confirming or adjusting diagnosis or staging; determining the adequacy of surgical treatment; recommending additional testing; and finalizing a treatment plan. Referrals for additional consultations, such as supportive/rehabilitative care and evaluation of clinical trial eligibility, also were considered. These activities were summarized in writing and/or communicated verbally to the treatment team. Patients were not included. In the clinic format (n = 3), [32] [33] [34] patients were evaluated by a series of relevant, co-located oncology specialty providers. Patient records were reviewed, and patients could Cancer September 15, 2018 undergo additional testing or be evaluated by supportive/ rehabilitative care providers. Typically, the multidisciplinary plan was summarized in a written progress note. In the integrated conference/clinic format (n = 20), [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] patients were seen by co-located providers who also convened during the clinic day to formally review all cases and finalize the treatment recommendations, which were subsequently discussed with the patient. Two studies did not specify the delivery format. 55, 56 Descriptions of the structural and operational components of the MTP intervention were generally limited, which restricted interpretations about the correlation between structural and operational components and the observed outcomes.
Outcomes
The diverse range of outcomes examined across studies is presented in Table 1 Table 2 12-56 summarizes the outcome data with studies grouped according to MTP delivery format and disease site. Sixteen of 19 studies demonstrated an association between MTP and receipt of guideline-concordant treatment. In 3 studies, differential effects were reported according to disease site 25, 38 and disease risk status. 49 Across disease sites and formats, clinically significant alterations in diagnostic/staging and/or treatment recommendations resulted consistently from MTP. Positive effects of MTP on timeliness were reported in 11 of 13 studies. However, in patients with thoracic cancer, MTP delivered through an integrated conference/ clinic format failed to produce positive effects on time to diagnosis or to treatment. 52 MTP effects on timeliness also varied by disease site and physician engagement. 56 MTP improved survival outcomes in 9 of 16 studies. There was heterogeneity in the approach to survival analysis, and variation in both the length of follow-up and whether covariates such as age and disease stage were included in the modeling. Six of 7 studies that did not demonstrate an association with survival 25, 26, 30, 43, 46, 52 were underpowered.
Mixed effects of MTP on indicators of trial access (eligibility evaluation and enrollment) were observed. MTP increased the likelihood of being evaluated for trial eligibility in patients who had lung cancer 28 but not in those who had mixed disease sites. 56 Similarly, although, among patients who had solid tumors 26 or gynecologic malignancies, 16 MTP increased trial enrollment, it failed to do so in those who had lung cancer 29 or colorectal cancer. 37 
DISCUSSION
We critically appraised evidence of the effectiveness of MTP within US cancer treatment settings and observed that, irrespective of delivery format, MTP favorably affects a wide range of care quality, patient-focused, and health services outcomes. Consistent effects were observed on 2 outcomes that directly reflect cancer care quality: guideline-concordant treatment recommendations and clinically significant alterations in diagnosis/ • In total, 30% were eligible for a trial, and 24% subsequently enrolled; patient discussions of eligibility were documented in 44%, a rate lower than documented discussions of other MTP recommendations (P < .01)
• Those with documented trial eligibility discussions were 2.5 times more likely to enroll in a trial (P < . • MTP associated with 21% increase in receipt of guideline-concordant adjuvant therapy
• No effects on time from surgery to adjuvant treatment (all P > .05)
• MTP associated with optimized surgical technique (P < .05) • Differential survival effects by disease site: MTP improved 3-y overall survival in patients with rectal cancer (P < .05) but not colon cancer (P = .07); no effect of MTP on 3-y disease-free survival in either colon cancer (P = .7) or rectal cancer (P = Cancer September 15, 2018 staging and/or the treatment plan. Our results also demonstrate that MTP is associated with improvements in timeliness, surgical technique, and survival, although statistically significant effects were not consistently observed. Our findings are comparable to those reported when MTP effectiveness was evaluated in health systems in other countries 4, [57] [58] [59] [60] and align with the conclusions of reviews that addressed MTP only in the context of a single disease site 6, 7, 61, 62 or MTP outcome. 6, 63 Taken together, these results add to the body evidence supporting MTP as a critical element in US standards of cancer care. 3, 64 Our findings should be interpreted cautiously, because many of the studies included in this review used research designs with sources of bias, which may limit the strength and generalizability of our conclusions. Moreover, although the criteria used to rate study quality were developed explicitly to appraise single-arm or cohort study designs, we acknowledge that the resultant ratings were somewhat liberal. The methodological quality of the studies was limited by small samples, single-institution studies, and the lack of randomized trials. Conducting randomized studies of MTP will require novel designs, because MTP has been established as a quality standard. 3 In addition, although many of the studies reported that MTP altered the recommended patient management plan, fewer studies measured the extent to which MTP recommendations were implemented. Nonadherence to MTP recommendations may attenuate the effects on clinical outcomes such as survival. In addition, the potential impact of clinic processes on shared decision making and patient adherence (2 factors that also may affect outcomes) were not explicitly addressed.
The included studies also lacked detail about the structural and operational components of the MTP interventions, including team composition and decision-making processes. Variability in how MTP was implemented may have contributed to the mixed effects on receipt of guideline-concordant treatment, survival, and access to trials. It has been demonstrated that contextual and organizational factors surrounding MTP influence the quality of multidisciplinary decision making 60, 65 ; however, the direct influence of these factors on MTP has had limited study. Guidelines and quality indicators for MTP have been advanced, 66, 67 and tools for performance evaluation also have had preliminary validation. 68 If they are endorsed as applicable in US settings, then these methods could promote MTP intervention fidelity and more consistent reporting. Moreover, although structural and operational factors may act uniquely and Cancer September 15, 2018 synergistically to produce the beneficial effects of MTP, studies to date have not been designed to isolate the active ingredients/mechanisms in MTP. In future MTP studies, consistency in reporting the structural and operational components will be crucial to understanding which formats improve outcomes, for which patient groups, and by what mechanism(s).
This review reveals several knowledge gaps that should be addressed in future studies evaluating MTP interventions. First, patient-focused outcomes, such as patient engagement, shared decision-making, and adherence, were not measured in the included studies. This gap is salient, because MTP may exert strong effects on these outcomes. 1 Two of 4 studies that examined patient Cancer September 15, 2018 experience reported no associations with MTP. 26, 45 Although it is possible that ratings of satisfaction have limited responsiveness to MTP effects, 45 MTP strengthened engagement and reduced wait time and travel distance, suggesting that additional research examining MTP effects on patient experiences of care is warranted. Only 2 studies addressed cost. Although MTP is relatively inexpensive 30 and reduces expenditures during diagnosis/staging, 28 2 recent systematic reviews 6,7 concluded that evidence of MTP cost effectiveness remains sparse. Second, comorbidities and palliative care were rarely incorporated into MTP. Efforts are needed to establish MTP as an efficient and effective approach that can individualize treatment to accommodate comorbidities and integrate palliative care. 69 We also excluded studies that addressed molecular profiling in MTP. This is a rapidly expanding component of contemporary cancer treatment planning, and its important implications for MTP processes and outcomes deserve focused examination. 70 Finally, there was limited consideration of how technologies like videoconferencing and other mobile health tools 71 might expand access to MTP and optimize communication and coordination among providers.
Conclusion
Across delivery formats, MTP has favorable effects on diverse outcomes. Structural and operational elements of MTP were underspecified and variable, making it difficult to isolate the components and processes directly responsible for these beneficial outcomes. Consensus standards for MTP would support consistent implementation in practice and strengthen the rigor and interpretability of future research. This review adds to the body of evidence that supports MTP as an essential component of quality cancer care, motivates the development of more rigorous evidence for the effectiveness of MTP, and sets the stage for the validation of indicators of effective MTP that can be used as performance metrics within value-based care-delivery models.
